43 States & Territories Seek Court Approval of $400 Million Generic Drug Price-Fixing Settlement

Key Takeaways

• $400 Million Settlement: A coalition of 43 states and territories is seeking court approval of a settlement with Sandoz and Fougera over allegations of widespread generic drug price-fixing.
• Total Payments Reach $469 Million: Including earlier agreements with other states, Sandoz's total settlement payments are expected to reach approximately $469 million.
• Years of Alleged Collusion: Investigators gathered millions of records as part of an investigation into suspected price coordination, market allocation and restrictions on competition.
• Corporate Accountability and Compliance Reforms: The proposed agreement addresses allegations involving Sandoz's international affiliates and requires internal reforms intended to strengthen antitrust compliance.
• Consumer Restitution: Consumers who purchased certain generic prescription medicines between May 2009 and December 2019 may qualify for compensation.

Deep Dive

A coalition of 43 states and territories has asked a federal court to approve a $400 million settlement with Sandoz and Fougera Pharmaceuticals, two generic drug manufacturers accused of participating in a widespread conspiracy to fix prescription drug prices, divide markets and suppress competition.

The motion for preliminary approval was filed October 1 in the U.S. District Court for the District of Connecticut, advancing an agreement first announced in principle on August 3. All 43 participating jurisdictions have since signed on. Including payments associated with previous settlements Sandoz reached with other states, the company is expected to pay approximately $469 million to resolve claims brought by state attorneys general.

The settlement would resolve allegations that Sandoz and Fougera participated in years of coordinated conduct that artificially inflated the prices of generic prescription medicines. It also covers claims against several current and former international affiliates of Sandoz, including Novartis AG, Sandoz AG and Sandoz Group AG, which the states accused of participating in the alleged anticompetitive activity and fraudulently transferring assets to avoid liability.

Sandoz has agreed to a series of internal reforms intended to strengthen antitrust compliance and prevent future restrictions on competition. Those commitments form part of the proposed settlement alongside the financial payments, although the agreement remains subject to court approval.

The settlement comes as state attorneys general prepare for the first trial in the broader generic drug antitrust litigation, scheduled for February 2027 in Hartford. The cases have been building since 2016 and now encompass allegations against nearly 50 major generic pharmaceutical manufacturers, with investigators examining suspected agreements to fix prices, allocate customers and markets, and rig bids involving hundreds of medicines.

A Decade of Alleged Collusion

The investigation began with a comparatively narrow complaint in 2016 involving 15 generic drugs, 18 corporate defendants and two individual defendants. It subsequently expanded into a series of lawsuits examining conduct across much of the generic pharmaceutical industry.

A second complaint, filed in 2019, named Teva Pharmaceuticals and 21 major generic drug manufacturers, along with 16 individual senior executives. A third case, which is scheduled to be tried first, concerns 80 topical generic medicines representing billions of dollars in U.S. sales. That complaint names 26 corporate defendants and 10 individuals.

Earlier in 2026, the states filed a fourth complaint targeting the alleged involvement of Sandoz's international affiliates and claims that assets had been transferred fraudulently to shield them from liability.

The scale of the investigation has been considerable. According to the Connecticut Attorney General's Office, investigators assembled more than 20 million documents and a database containing millions of telephone records, including contact information for more than 600 sales and pricing personnel working in the generic pharmaceutical industry.

The complaints describe competing executives maintaining regular contact through telephone calls, emails and text messages, as well as meetings at industry dinners, lunches, cocktail parties and golf outings. Investigators also obtained a two-volume notebook kept by a cooperating witness, containing contemporaneous accounts of conversations with competitors and internal company meetings over several years.

The states allege that this network of professional relationships helped manufacturers coordinate pricing decisions and discourage competition. Their complaints describe executives using expressions such as “fair share,” “playing nice in the sandbox” and “responsible competitor” when discussing their dealings with rival companies.

Those records are central to the states' allegations that the suspected price-fixing was sustained through repeated contacts among competitors rather than isolated agreements concerning individual medicines. The litigation has also involved cooperation from former industry executives, including two former Heritage Pharmaceuticals officials who entered into settlement agreements with the states.

The allegations show the antitrust exposure associated with informal communications among competitors, particularly when employees responsible for pricing and commercial decisions exchange information outside established business channels. The alleged conduct also raises questions about the effectiveness of internal oversight at companies whose employees maintained extensive relationships with direct competitors.

The proposed settlement would require Sandoz to introduce internal reforms addressing competition and antitrust compliance. The public announcements describe those measures as meaningful injunctive terms but do not provide a detailed account of each requirement.

Financial Recovery and Corporate Accountability

The proposed $400 million agreement follows settlements with Glenmark, Lannett, Bausch, Apotex, Heritage and Heritage's parent company, Emcure, which together totaled $96.5 million.

The additional $69 million associated with Sandoz's earlier settlements brings its total payments to approximately $469 million. That figure should be distinguished from the $96.5 million recovered through agreements with the other manufacturers.

The agreement also addresses the states' allegations that Sandoz's international affiliates participated in the underlying conduct and fraudulently transferred assets to avoid liability. Those claims have extended the litigation into questions of corporate structure and responsibility for alleged misconduct across affiliated entities.

Washington and Idaho also obtained restitution provisions for affected businesses, the only two states in the coalition to secure that form of relief. In Washington, eligible businesses may include those that indirectly purchased covered medicines or reimbursed purchasers for some or all of their costs during the settlement period.

The states have not yet completed the court approval process. Preliminary approval would permit the agreement to advance toward final consideration, while the wider antitrust litigation continues against other defendants.

Connecticut Attorney General William Tong, whose office is leading the multistate litigation, said the agreement would provide restitution to consumers while the states prepare for their first trial.

The February 2027 proceedings will concern a separate group of defendants and medicines, with the states continuing to pursue allegations arising from the industry's pricing practices. After ten years of investigations, multiple lawsuits and successive settlements, much of the broader case remains before the courts.

The GRC Report is your premier destination for the latest in governance, risk, and compliance news. As your reliable source for comprehensive coverage, we ensure you stay informed and ready to navigate the dynamic landscape of GRC. Beyond being a news source, the GRC Report represents a thriving community of professionals who, like you, are dedicated to GRC excellence. Explore our insightful articles and breaking news, and actively participate in the conversation to enhance your GRC journey.